目的 探究心可舒片干预动脉粥样硬化（AS）作用的分子机制，对于心可舒片二次开发和临床应用提供参考。方法 用整合药理学平台对心可舒片干预AS的关键靶点和通路进行预测，探究其干预AS的分子机制。结果 通过建立心可舒片“中药-成分-靶点-通路”网络进行预测和分析，得到相关有效成分80个，确定了B4GALT4、B4GALT2、PRKCD、GCK、GNB1等关键靶点，明确了内分泌系统、甲状腺激素、神经系统、雌性激素和趋化因子等富集通路与其抗AS作用相关。结论 心可舒片通过对PI3K/Akt/eNOS和Raf/MEK/ERK途径的共同调节，保护血管内皮细胞，从而达到干预AS的效果。

Objective To explore the mechanism of the intervention of Xinkeshu Tablets (XKST) on atherosclerosis (AS) and provide reference for the secondary development and clinical application of XKST. Methods The integrated pharmacology platform was used to predict the key targets and pathways of the intervention of XKST on AS and its molecular mechanism was also explored. Results In the integrative analysis of heterogeneous network of "TCM-component-target-pathway", 80 relevant effective ingredients were found, including B4GALT4, B4GALT2, PRKCD, GCK, GNB1, and other key targets; Endocrine system, thyroid hormone signaling pathway, nervous system, estrogen signaling pathway, and chemokine signaling pathway were key pathways related with its anti-atherosclerosis. Conclusion According to the analysis and prediction of the enrichment information, the effect of XKST on common regulating PI3K/Akt/eNOS and Raf/MEK/ERK signaling pathway and protecting vascular endothelial cells is first prompted, thus achieving the intervention in AS.

山东省重大产业专项：国家基药大品种心可舒片二次深度开发（2015ZDZX07002）；国家重大新药创制重大专项课题：中药复方药理学研究与药效评价关键技术（2009ZX09502-015）；山东省自主创新和成果转化课题：药物安全性评价和适宜于抗肿瘤及缺血性脑血管疾病多靶点和复方新药成药性评价关键技术研究（2014ZZCX02104）；泰山学者工程专项经费资助（Ns201511107）